Content is educational and planning-oriented. It does not replace diagnosis, treatment, or personalized medical advice from a licensed healthcare professional. Outcomes vary by individual case.
ICL (Implantable Collamer Lens) surgery is FDA-approved for myopia correction ranging from -3.0 to -20.0 diopters, with the age range recently expanded to include adults 21-60 years old.
Unlike LASIK, ICL preserves corneal tissue and is reversible—the lens can be removed or replaced if needed, which may benefit younger patients or those with evolving prescriptions.
The EVO model's central port design eliminates the need for preoperative iridotomy, simplifying the surgical preparation process.
Real-world safety data from over 17,000 adverse event reports provides insight into complication patterns, though voluntary reporting has inherent limitations.
Candidacy depends on specific eye measurements including anterior chamber depth of at least 3.00mm and adequate endothelial cell density—comprehensive evaluation is essential.
Educational information only
This content is general education and does not replace evaluation by a licensed clinician. If you have symptoms, complications, or urgent concerns, seek in-person medical care.
What Is the ICL?
The Implantable Collamer Lens (ICL) represents an alternative approach to vision correction that works differently from laser-based procedures. Rather than reshaping the cornea, the ICL is a thin, prescription lens that is surgically placed inside the eye to correct refractive errors [S3].
The lens is positioned behind the iris (the colored part of your eye) and in front of the eye's natural crystalline lens. This placement allows light to focus properly on the retina, reducing or eliminating the need for glasses or contact lenses. The material used in the ICL is called Collamer, a proprietary blend of collagen and polymer designed to be biocompatible with the eye's internal environment [S3].
How ICL Differs from Laser Vision Correction
Understanding the fundamental differences between ICL and procedures like LASIK or PRK can help you evaluate which approach may align with your vision goals and eye health considerations [S3]:
Corneal preservation: Unlike LASIK, which creates a corneal flap and removes underlying tissue to reshape the cornea, ICL surgery does not alter the corneal structure. This preservation may be relevant for patients with thinner corneas or those concerned about corneal tissue removal.
Reversibility: The ICL can be removed or replaced if needed, whereas laser corrections are permanent alterations to the cornea. This reversibility may provide flexibility for patients whose prescriptions change over time or who may develop age-related eye conditions.
Correction range: ICL can address higher levels of myopia than what LASIK typically handles. For patients with severe nearsightedness (-8.0 diopters or higher), lens-based approaches like ICL may offer correction capabilities beyond laser surgery limits.
Surgical mechanics: LASIK typically takes approximately 15 minutes per eye and uses an excimer laser to reshape the cornea. ICL surgery involves creating a small incision through which the folded lens is inserted and positioned behind the iris [S3].
Why the Central Port Design Matters
A significant advancement in ICL technology came with the EVO model's central port design (called KS-AquaPORT). Earlier ICL models required patients to undergo a separate procedure called peripheral iridotomy, where small holes were created in the iris to ensure proper fluid flow and prevent pressure buildup [S3].
The EVO model's integrated central port eliminates the need for this additional procedure. The port allows physiologic aqueous humor circulation between the anterior and posterior chambers of the eye, maintaining normal intraocular pressure dynamics without surgical modification to the iris [S3]. This advancement simplifies the overall treatment process and removes an additional procedural step from the patient's experience.
Are You a Candidate for ICL?
Candidacy for ICL surgery depends on meeting specific criteria established through FDA approvals and clinical considerations. These requirements help ensure the procedure can be performed safely and effectively [S3].
Who May Benefit from ICL
Based on FDA-approved indications, ICL surgery may be appropriate for adults who meet refractive and anatomical criteria [S2][S3]:
Myopia range: The ICL is approved for correcting myopia from -3.0 diopters to -20.0 diopters at the spectacle plane. This wide range makes ICL suitable for patients with moderate to severe nearsightedness who may exceed LASIK correction limits.
Myopic astigmatism: For patients with astigmatism alongside myopia, toric ICL models are available to address cylinder measurements from 1.0 diopter to 4.0 diopters [S3].
Age requirements: As of the February 2026 FDA expansion, the approved age range includes adults from 21 to 60 years old. This expansion potentially makes the procedure available to approximately 8 million additional refractive patients in the United States alone [S1].
Stable refraction: Candidates should have had no change greater than 0.5 diopter in their prescription for at least one year prior to implantation [S3].
Required Eye Measurements and Criteria
Beyond refractive error, specific anatomical measurements are essential for determining candidacy and surgical planning [S3]:
Anterior chamber depth (ACD): The front chamber of the eye must be at least 3.00 millimeters deep, measured from the corneal endothelium to the anterior lens surface. This measurement ensures adequate space for the ICL to be positioned without interfering with surrounding structures.
Endothelial cell density: The cornea's endothelial cell layer must have sufficient cell density to maintain corneal clarity and function over time. Requirements vary by age, as cell density naturally decreases with age. Patients with lower baseline density may face higher long-term risks.
White-to-white distance: This measurement describes the horizontal diameter of the cornea and helps determine appropriate ICL sizing for proper fit and positioning.
Angle assessment: The eye's anterior chamber angle must be evaluated to ensure proper drainage anatomy and reduce the risk of angle closure or elevated intraocular pressure.
When ICL May Not Be Appropriate
Certain conditions may preclude ICL surgery or require careful consideration [S3]:
Anterior chamber depth less than 3.00mm
Insufficient endothelial cell density for age
Moderate to severe glaucoma
Active eye infections or inflammation
Pregnancy or nursing (hormonal changes can affect refraction)
Uncontrolled diabetes affecting the eyes
Certain autoimmune conditions affecting wound healing
Cataract development or significant lens opacity
Individual Candidacy Varies
Not everyone seeking ICL surgery will qualify based on anatomical factors. A comprehensive eye examination with detailed imaging and measurements is necessary to determine individual candidacy. The information provided here is educational and does not replace personalized evaluation by a qualified ophthalmologist.
What Does the ICL Procedure Involve?
Understanding the procedural journey can help you prepare for each stage of treatment and recovery.
Before Surgery: Evaluation and Planning
The preoperative process involves extensive evaluation to confirm candidacy and ensure precise surgical planning [S3]. This typically includes:
Comprehensive eye examination: A thorough assessment of refractive error, visual acuity, and ocular health. This exam goes beyond a standard eye check and includes specialized testing for refractive surgery candidacy.
Anterior segment imaging: Detailed measurements of anterior chamber depth, corneal topography, and white-to-white distance using imaging technology such as Scheimpflug tomography or anterior segment OCT.
Endothelial cell count: Specular microscopy to assess endothelial cell density and morphology, ensuring adequate cellular reserve for long-term corneal health.
Pupil evaluation: Assessment of pupil size under various lighting conditions, as large pupils may influence lens selection and surgical technique.
Discussion and informed consent: A conversation about the procedure, potential risks, expected outcomes, and alternatives. This is an opportunity to ask questions and understand what the procedure can and cannot accomplish for your specific situation.
The Surgical Procedure
ICL implantation is typically performed as an outpatient procedure. While specific techniques may vary among surgeons, the general process follows this sequence [S3]:
The eye is numbed with topical anesthesia to ensure comfort during the procedure. A small incision—typically less than 3 millimeters—is created at the edge of the cornea. Through this incision, the ICL, which has been folded for insertion, is carefully advanced into the eye using specialized instruments.
Once inside the eye, the ICL unfolds and is positioned behind the iris and in front of the natural crystalline lens. The lens is centered and stabilized, with the footplates resting in the ciliary sulcus. In most cases, no stitches are required, as the self-sealing incision maintains its integrity.
The procedure typically takes approximately 20-30 minutes per eye, though this may vary. Many surgeons perform the procedure on one eye first, with the second eye treated days to weeks later, though some protocols allow for bilateral same-day surgery under appropriate circumstances.
Recovery and Postoperative Care
Recovery from ICL surgery is generally rapid compared to some other refractive procedures, though individual experiences vary [S3]:
Immediate postoperative period: Patients may experience mild discomfort, tearing, or light sensitivity immediately after surgery. Vision may be blurry initially as the eye adjusts. Most patients notice significant visual improvement within the first 24-48 hours.
Activity restrictions: Surgeons typically recommend avoiding strenuous activities, swimming, and eye rubbing for a specified period. Contact with water (showering carefully, avoiding pools) may be restricted initially to reduce infection risk.
Medication regimen: A course of topical anti-inflammatory and antibiotic eye drops is prescribed to support healing and reduce the risk of infection or inflammation. Patients should follow the prescribed drop schedule carefully.
Follow-up schedule: Regular postoperative visits allow the surgeon to monitor healing, assess visual outcomes, check intraocular pressure, and evaluate lens positioning. These visits typically occur at day one, week one, month one, and then at longer intervals as healing progresses.
Understanding the Evidence and Safety
Evaluating the evidence base helps prospective patients understand what clinical research and real-world data reveal about ICL safety and effectiveness.
What Clinical Trials Show
FDA clinical trial data provides controlled evidence regarding ICL outcomes [S1]:
Safety profile: Three-year FDA clinical trial data demonstrated a safety index of 1.25 at three years, indicating stable or improved best-corrected visual acuity compared to preoperative measurements. No cases of pupillary block or pigment dispersion were reported during the trial period [S1].
Visual acuity outcomes: In FDA trials, patients achieved strong visual results [S1]:
98.4% of patients with 7 diopters or less of myopia achieved 20/20 or better uncorrected vision at three years
86.9% of patients with more than 7 to 10 diopters achieved 20/20 or better
83.8% of highly myopic patients (more than 10 diopters) achieved 20/40 or better uncorrected vision at three years
Complication rates: Anterior subcapsular cataract occurred in 0.16% of cases during the trial period [S1]. The trial did not report cases of pupillary block, which had been a historical concern with earlier ICL designs.
Real-World Safety Data
Beyond clinical trials, real-world evidence from the FDA MAUDE (Manufacturer and User Facility Device Experience) database provides insight into outcomes across a broader population [S2]:
A comprehensive analysis of FDA MAUDE reports between 2015-2023 examined 17,482 adverse event reports related to EVO and EVO+ ICL implantations [S2]. Key findings from this analysis include:
Event distribution: Over half of the reports documented no clinical signs or symptoms, meaning the majority of reported events did not result in documented patient harm. Many reports were filed for quality or device-related concerns without clinical sequelae. It is important to note that MAUDE data reflects voluntary reporting, which may undercount or overcount certain events and cannot establish causation between the device and reported events [S2].
Visual complaints: Blurred vision was the most frequently reported visual complaint, with relatively higher reporting frequency in EVO+ groups (the larger lens model for higher corrections) [S2].
Intraocular pressure: Elevated intraocular pressure and glaucoma events were more commonly reported among EVO+ recipients, which may relate to the larger lens size or other factors [S2]. These conditions are typically manageable with medication or, in some cases, lens removal.
Reporting trends: The annual number of reported adverse events showed a consistent upward trend throughout the study period, which researchers attribute to increased procedure volume rather than declining safety [S2].
The MAUDE database represents voluntary reporting, which may undercount or overcount certain events. Additionally, the database cannot establish causation between the device and reported events. These data provide a signal for potential concerns but should be interpreted in context with controlled clinical trial evidence.
Common and Rare Complications
Understanding the spectrum of potential complications helps set realistic expectations [S2][S3]:
Common and generally manageable:
Mild visual disturbances such as halos or glare, particularly in low-light conditions
Temporary elevated intraocular pressure, often related to retained viscoelastic surgical fluid
Minor inflammation that responds to topical medication
Small amounts of pigment dispersion (loss of iris pigment)
Less common but clinically significant:
Cataract formation, particularly anterior subcapsular cataracts, which may require lens removal
Persistent elevated intraocular pressure requiring medication or surgical intervention
Vault-related issues—too low may increase cataract risk, too high may increase pupillary block risk
Rotation or malposition of toric lenses (for astigmatism correction)
Rare but serious:
Infection (endophthalmitis), which requires urgent medical attention
Toxic anterior segment syndrome (TASS), an inflammatory reaction to substances introduced during surgery
Significant hemorrhage or hyphema
Severe corneal endothelial cell loss
Long-Term Outcomes and Reversibility
Several factors influence long-term outcomes and should be considered when evaluating ICL as a vision correction option [S3]:
Vault dynamics: The space between the ICL and the natural crystalline lens—called vault—ideally measures approximately 250-750 microns. Vault may change over time due to various factors. Vault that is too low may increase cataract risk; vault that is too high may increase pupillary block risk. Surgeons monitor vault during follow-up visits [S3].
Reversibility: Unlike laser vision correction, ICL surgery is reversible. The lens can be removed if complications develop, if vision needs change significantly, or if cataract surgery becomes necessary in later decades. This reversibility distinguishes lens-based procedures from corneal surgery.
Future cataract surgery: If cataracts develop in later life, the ICL can typically be removed during cataract surgery, and a new intraocular lens implanted. The presence of an ICL does not preclude future cataract treatment but may add complexity to the surgical planning.
Endothelial cell considerations: Long-term endothelial cell density changes are monitored through periodic specular microscopy. While significant cell loss is uncommon, ongoing monitoring allows for early detection and management if concerns arise.
Can ICL Be Combined with Other Procedures?
In certain circumstances, ICL surgery may be combined with or followed by additional procedures to address specific vision needs [S3]:
Toric ICL for astigmatism: For patients with both myopia and astigmatism, toric ICL models can address both refractive errors simultaneously in a single implantation, eliminating the need for separate astigmatism correction procedures.
Enhancement procedures: In cases where residual refractive error remains after ICL implantation, laser vision correction such as LASIK or PRK may be performed as an enhancement to fine-tune outcomes. This combination approach requires careful evaluation and planning, as the corneal tissue must be adequate for laser treatment.
Cataract surgery: For patients who develop cataracts after ICL implantation, the ICL can be removed during cataract surgery and replaced with an appropriate intraocular lens. This staged approach allows patients to benefit from ICL correction for many years before needing lens replacement.
The feasibility of combination procedures depends on individual anatomy, the amount of correction needed, and the surgeon's assessment of risks and benefits. Not all patients are candidates for combined approaches, and separate procedures may be recommended instead.
Making an Informed Decision
Questions to Ask Your Ophthalmologist
Before proceeding with ICL surgery, consider discussing these topics with your eye care provider:
Based on my specific measurements, am I a good candidate for ICL surgery?
What are my expected visual outcomes given my prescription and eye anatomy?
What is your experience with ICL implantation, and what is your specific complication rate?
What preoperative testing will be performed, and what do the results indicate about my candidacy?
What does your postoperative monitoring schedule include, and how would any complications be managed?
What are the warning signs I should watch for after surgery, and what should prompt immediate attention?
How does ICL fit with my long-term eye health needs and potential future conditions?
Evaluating Your Surgeon
Surgeon experience and facility standards can significantly influence outcomes [S3]:
Surgeon considerations: Ask about the ophthalmologist's training specifically in ICL surgery, their volume of ICL procedures, and their outcomes data. Surgeons who regularly perform ICL implantation tend to have more refined techniques and better ability to manage any issues that arise.
Facility considerations: Confirm that the surgical facility maintains appropriate sterilization protocols, emergency equipment, and trained staff. Accreditation by recognized organizations may indicate adherence to established safety standards.
Device verification: Confirm that authentic STAAR Surgical lenses are being used. Request information about lens sourcing and batch tracking if this is important to you.
Alternatives If ICL Is Not Suitable
For patients who do not qualify for ICL or prefer alternative approaches, other options exist [S3]:
LASIK or PRK: For patients with adequate corneal thickness and appropriate prescriptions, laser vision correction may remain an option. These procedures are permanent but have extensive safety data.
Refractive lens exchange: For older patients or those with early lens changes, removing the natural lens and replacing it with a prescription intraocular lens may address both refractive error and potential future cataracts.
Glasses or contact lenses: For some patients, traditional correction remains the safest and most appropriate option, particularly if ocular anatomy or other factors make surgical correction inadvisable.
Results Vary Significantly
Outcomes from ICL surgery depend on individual anatomy, healing response, surgical technique, and many other factors. No website or information source can predict your specific results. A comprehensive evaluation by a qualified ophthalmologist is essential for understanding what ICL surgery may accomplish for your particular situation.
For International Patients
If you are considering traveling for ICL surgery, additional planning considerations apply. Understanding surgical facility standards and verifying surgeon credentials are essential steps in your research.
Surgeon verification: Research the ophthalmologist's credentials, training, and experience. Board certification and specific ICL training are important qualifications to confirm. You can find qualified ophthalmologists through reputable directories and professional societies.
Facility standards: Inquire about surgical facility accreditation, sterilization protocols, and emergency preparedness. Facilities meeting international standards may provide additional confidence.
Preoperative evaluation: Understand what tests will be performed and whether they align with FDA/AAO recommendations. Some international providers may offer preoperative evaluation remotely before travel.
Follow-up care: Plan how postoperative monitoring will be managed. Extended travel after surgery may be recommended to allow for initial follow-up visits. Understanding how to coordinate care across borders is important.
Communication: Confirm that you can communicate effectively with your surgical team, both before and after the procedure. Clear communication about expectations, concerns, and any postoperative issues is essential.
International patient coordination: Many facilities offer support services for patients traveling from abroad, including transportation, accommodation assistance, and multilingual staff. These services can help streamline your medical travel experience.
2.“Real-World Safety Profile of EVO and EVO+ Implantable Collamer Lenses: A Retrospective Study Based on FDA Surveillance Data.” 2025. Accessed 2026-02-19.https://pmc.ncbi.nlm.nih.gov/articles/PMC12534635/
